Notably, targeting this B-ALL-associated PD-1 expression conferred clinical benefits by restoring NK-mediated tumor cell killing [45] in vitro and eliminating tumor cells in vivo in mice engrafted with B-ALL. This evidence concerns the gene PDCD1 and acute lymphoblastic leukemia.